Search Videos by Topic or Participant
Browse by Series:

Novel Therapies Needed for Muscle-Invasive Bladder Cancer

Insights From: Dean F. Bajorin, MD, MSKCC; Daniel P. Petrylak, MD, Yale;Evan Y. Yu, MD, Seattle Cancer Care
Published: Saturday, Jun 06, 2015
For High-Definition, Click
The PD-L1 inhibitor atezolizumab (formally MPDL3280A) was granted breakthrough therapy designation from the FDA in June 2014, representing a future advance. In the study that led to this designation, the objective response rate with atezolizumab was 43% in PD-L1 positive patients (IHC 2/3). At the time of the data cutoff in 2014, 94% of patients had ongoing responses.

At this time, there are still no FDA-approved agents for the treatment of muscle-invasive bladder cancer, Dean F. Bajorin, MD, states. Combining immunotherapies and angiogenic inhibitors offers possibilities for future treatments, states moderator Daniel P. Petrylak, MD. However, these combinations also pose greater risk for toxicities, he adds.

While promising as treatments, immunotherapies can cause pseudoprogression, during which tumors increase in size but the increase is not actual disease progression. Due to the potential for pseudoprogression with these agents, Petrylak suggests that current response criteria must be reconsidered. This phenomenon, explains Bajorin, may be infiltration, partial growth, or just a delay in the immune system responding to the antigens. Evan Y. Yu, MD, notes that current clinical trials evaluating checkpoint inhibitors have accounted for the potential of pseudoprogression, and individuals may be treated beyond initial progression in these trial designs.
Slider Left
Slider Right
For High-Definition, Click
The PD-L1 inhibitor atezolizumab (formally MPDL3280A) was granted breakthrough therapy designation from the FDA in June 2014, representing a future advance. In the study that led to this designation, the objective response rate with atezolizumab was 43% in PD-L1 positive patients (IHC 2/3). At the time of the data cutoff in 2014, 94% of patients had ongoing responses.

At this time, there are still no FDA-approved agents for the treatment of muscle-invasive bladder cancer, Dean F. Bajorin, MD, states. Combining immunotherapies and angiogenic inhibitors offers possibilities for future treatments, states moderator Daniel P. Petrylak, MD. However, these combinations also pose greater risk for toxicities, he adds.

While promising as treatments, immunotherapies can cause pseudoprogression, during which tumors increase in size but the increase is not actual disease progression. Due to the potential for pseudoprogression with these agents, Petrylak suggests that current response criteria must be reconsidered. This phenomenon, explains Bajorin, may be infiltration, partial growth, or just a delay in the immune system responding to the antigens. Evan Y. Yu, MD, notes that current clinical trials evaluating checkpoint inhibitors have accounted for the potential of pseudoprogression, and individuals may be treated beyond initial progression in these trial designs.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x